BRCA1 and ovarian carcinoma: Reasons for exclusions were single arm studies, drug taken off the market due to lack of efficacy in a post-marketing trial (olaratumab for soft-tissue sarcoma), and data unavailable despite contact with study authors (olaparib maintenance in relapsed BRCA1/2-mutated ovarian cancer).